Dataset Information

Lactylation omics of rabbit rotator cuff tears

ABSTRACT: In this study, we conducted lactylation omics on rabbit rotator cuff tear samples and identified 2624 modification sites on 851 proteins. We obtained results on modification intensity, subcellular localization, modified sites, differentially modified proteins and functional pathway enrichment. Basing on motifs, we proposed the "lysine co-lactylation modification effect" concept. Additionally, we surprisedly found the levels of lactate and lactylation is not perfectly consistent. While lactate continuously increased, lactylation initially decreased and then increased. Overall, lactylation widespreadly occurs and mainly localized in cytoplasm, mitochondria and nucleus, with its functional pathways enriching in RNA processing, DNA processing and cellular metabolism. We hope that lactylation intervention could provide new insights and therapies for the repair of rotator cuff tears.

INSTRUMENT(S):

ORGANISM(S): Leporidae

TISSUE(S): Tendon

SUBMITTER: Tong Pan

LAB HEAD: Tong Pan

PROVIDER: PXD062718 | Pride | 2026-04-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	XA00161LPLa.zip	Other
	XA00161LPLa_JG5D1_Fr1_E4_1_17097.d.zip	Other
	XA00161LPLa_JG5D1_Fr2_E7_1_17103.d.zip	Other
	XA00161LPLa_JG5D1_Fr3_B2_1_17109.d.zip	Other
	XA00161LPLa_JG5D2_Fr1_E5_1_17099.d.zip	Other

Items per page:

1 - 5 of 40

Publications

Lactylation omics of rabbit rotator cuff tear reveals differentially modified proteins and metabolic relating therapy targets.

Pan Tong T Liu Zhenlong Z

Frontiers in medicine 20260317

Proteins exert biological functions not only depending on abundance but also on regulation. Lactylation, a novel post-translational modification, can mediate metabolic reprogramming and epigenetic regulation, playing a crucial role in signal transduction, gene expression and cellular metabolism. Lactylation is also involved in various diseases, such as tumors, Alzheimer's disease, heart failure and myocardial infarction. However, there is little research in musculoskeletal system. In this study, ...[more]

PMID: 41924730

Similar Datasets

Project description:Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. Results: Pre-vaccination antibody levels to blood group A trisaccharide (BG-Atri) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with abundant anti-BG-Atri IgM relative to subjects with little or no pre-existing IgM for BG-Atri. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate specific antigen (PSA). Moreover, anti-BG-Atri IgM levels were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival. Conclusion: In addition to reporting a new potentially predictive biomarker for PROSTVAC-VF, this study highlights the potential of glycan microarray technology for personalized medicine. The overall study was a retrospective analysis of 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. The subjects were divided into a training set (n=28) and a validation set (n=113). A glycan microarray was used to profile pre-vaccination anti-glycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. For both the training set and validation set, the anti-glycan profiles were measured using four variations of serum dilution and isotype specific secondary antibody (IgM at 1:50, IgG at 1:50, total Ig at 1:50, and total Ig at 1:200). Total immunoglobin (IgM + IgG + IgA) levels for the training set measured at serum dilution of 1:50 are detailed here. The screen for predictive biomarkers identified anti-glycan antibodies that consistently stratified subjects into groups with different Kaplan Meier survival estimates. Due to the potential for overfitting, a permutation test was used to estimate the false discovery rate. Raw data on superSeries GSE42184 record.

Project description:Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. Results: Pre-vaccination antibody levels to blood group A trisaccharide (BG-Atri) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with abundant anti-BG-Atri IgM relative to subjects with little or no pre-existing IgM for BG-Atri. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate specific antigen (PSA). Moreover, anti-BG-Atri IgM levels were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival. Conclusion: In addition to reporting a new potentially predictive biomarker for PROSTVAC-VF, this study highlights the potential of glycan microarray technology for personalized medicine. The overall study was a retrospective analysis of 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. The subjects were divided into a training set (n=28) and a validation set (n=113). A glycan microarray was used to profile pre-vaccination anti-glycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. For both the training set and validation set, the anti-glycan profiles were measured using four variations of serum dilution and isotype specific secondary antibody (IgM at 1:50, IgG at 1:50, total Ig at 1:50, and total Ig at 1:200). Total immunoglobin (IgM + IgG + IgA) levels for the training set measured at serum dilution of 1:200 are detailed here. The screen for predictive biomarkers identified anti-glycan antibodies that consistently stratified subjects into groups with different Kaplan Meier survival estimates. Due to the potential for overfitting, a permutation test was used to estimate the false discovery rate. Raw data on superSeries GSE42184 record.